Elevated Serum Soluble Programmed Cell Death Ligand 1 Concentration as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer Patients With Chemotherapy

Respiratory Research - United Kingdom
doi 10.1186/s12931-018-0885-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Elevated Serum Level of Angiopoietin-2 as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer

Tohoku Journal of Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

PLoS ONE
Multidisciplinary
2019English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Clinical Significance of Serum Soluble Death Receptor 5 Concentration in Locally Advanced Non‑small Cell Lung Cancer Patients

Oncology Letters
Cancer ResearchOncology
2014English

Programmed Death-Ligand 1 Expression Correlates With Diminished CD8+ T Cell Infiltration and Predicts Poor Prognosis in Anal Squamous Cell Carcinoma Patients

Cancer Management and Research
Oncology
2017English

P3.04-05 Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Increased Programmed Death Ligand-1 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy